Research programme: bone disease peptide therapeutics - Alize PharmaAlternative Names: I-HBD1 analogs - Alize Pharma
Latest Information Update: 29 Sep 2016
At a glance
- Originator University of Maine; University of North Carolina at Chapel Hill
- Developer Alize Pharma; New Paradigm Therapeutics
- Class Peptides
- Mechanism of Action Insulin-like growth factor binding protein 2 modulators; Osteoblast stimulants; Osteoclast inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteoporosis; Postmenopausal osteoporosis